2023-04-012024-03-312024-03-31false14402511CHRISTA GDP PHARMA LTD2024-04-1070229iso4217:GBPxbrli:pure144025112023-04-01144025112024-03-31144025112023-04-012024-03-31144025112022-10-06144025112023-03-31144025112022-10-062023-03-3114402511bus:SmallEntities2023-04-012024-03-3114402511bus:AuditExempt-NoAccountantsReport2023-04-012024-03-3114402511bus:FullAccounts2023-04-012024-03-3114402511bus:PrivateLimitedCompanyLtd2023-04-012024-03-3114402511core:WithinOneYear2024-03-3114402511core:AfterOneYear2024-03-3114402511core:WithinOneYear2023-03-3114402511core:AfterOneYear2023-03-3114402511core:ShareCapital2024-03-3114402511core:SharePremium2024-03-3114402511core:RevaluationReserve2024-03-3114402511core:OtherReservesSubtotal2024-03-3114402511core:RetainedEarningsAccumulatedLosses2024-03-3114402511core:ShareCapital2023-03-3114402511core:SharePremium2023-03-3114402511core:RevaluationReserve2023-03-3114402511core:OtherReservesSubtotal2023-03-3114402511core:RetainedEarningsAccumulatedLosses2023-03-3114402511core:LandBuildings2024-03-3114402511core:PlantMachinery2024-03-3114402511core:Vehicles2024-03-3114402511core:FurnitureFittings2024-03-3114402511core:OfficeEquipment2024-03-3114402511core:NetGoodwill2024-03-3114402511core:IntangibleAssetsOtherThanGoodwill2024-03-3114402511core:ListedExchangeTraded2024-03-3114402511core:UnlistedNon-exchangeTraded2024-03-3114402511core:LandBuildings2023-03-3114402511core:PlantMachinery2023-03-3114402511core:Vehicles2023-03-3114402511core:FurnitureFittings2023-03-3114402511core:OfficeEquipment2023-03-3114402511core:NetGoodwill2023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2023-03-3114402511core:ListedExchangeTraded2023-03-3114402511core:UnlistedNon-exchangeTraded2023-03-3114402511core:LandBuildings2023-04-012024-03-3114402511core:PlantMachinery2023-04-012024-03-3114402511core:Vehicles2023-04-012024-03-3114402511core:FurnitureFittings2023-04-012024-03-3114402511core:OfficeEquipment2023-04-012024-03-3114402511core:NetGoodwill2023-04-012024-03-3114402511core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3114402511core:ListedExchangeTraded2023-04-012024-03-3114402511core:UnlistedNon-exchangeTraded2023-04-012024-03-3114402511core:MoreThanFiveYears2023-04-012024-03-3114402511core:Non-currentFinancialInstruments2024-03-3114402511core:Non-currentFinancialInstruments2023-03-3114402511dpl:CostSales2023-04-012024-03-3114402511dpl:DistributionCosts2023-04-012024-03-3114402511core:LandBuildings2023-04-012024-03-3114402511core:PlantMachinery2023-04-012024-03-3114402511core:Vehicles2023-04-012024-03-3114402511core:FurnitureFittings2023-04-012024-03-3114402511core:OfficeEquipment2023-04-012024-03-3114402511dpl:AdministrativeExpenses2023-04-012024-03-3114402511core:NetGoodwill2023-04-012024-03-3114402511core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3114402511dpl:GroupUndertakings2023-04-012024-03-3114402511dpl:ParticipatingInterests2023-04-012024-03-3114402511dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3114402511core:ListedExchangeTraded2023-04-012024-03-3114402511dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3114402511core:UnlistedNon-exchangeTraded2023-04-012024-03-3114402511dpl:CostSales2022-10-062023-03-3114402511dpl:DistributionCosts2022-10-062023-03-3114402511core:LandBuildings2022-10-062023-03-3114402511core:PlantMachinery2022-10-062023-03-3114402511core:Vehicles2022-10-062023-03-3114402511core:FurnitureFittings2022-10-062023-03-3114402511core:OfficeEquipment2022-10-062023-03-3114402511dpl:AdministrativeExpenses2022-10-062023-03-3114402511core:NetGoodwill2022-10-062023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2022-10-062023-03-3114402511dpl:GroupUndertakings2022-10-062023-03-3114402511dpl:ParticipatingInterests2022-10-062023-03-3114402511dpl:GroupUndertakingscore:ListedExchangeTraded2022-10-062023-03-3114402511core:ListedExchangeTraded2022-10-062023-03-3114402511dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-10-062023-03-3114402511core:UnlistedNon-exchangeTraded2022-10-062023-03-3114402511core:NetGoodwill2024-03-3114402511core:IntangibleAssetsOtherThanGoodwill2024-03-3114402511core:LandBuildings2024-03-3114402511core:PlantMachinery2024-03-3114402511core:Vehicles2024-03-3114402511core:FurnitureFittings2024-03-3114402511core:OfficeEquipment2024-03-3114402511core:AfterOneYear2024-03-3114402511core:WithinOneYear2024-03-3114402511core:ListedExchangeTraded2024-03-3114402511core:UnlistedNon-exchangeTraded2024-03-3114402511core:ShareCapital2024-03-3114402511core:SharePremium2024-03-3114402511core:RevaluationReserve2024-03-3114402511core:OtherReservesSubtotal2024-03-3114402511core:RetainedEarningsAccumulatedLosses2024-03-3114402511core:NetGoodwill2023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2023-03-3114402511core:LandBuildings2023-03-3114402511core:PlantMachinery2023-03-3114402511core:Vehicles2023-03-3114402511core:FurnitureFittings2023-03-3114402511core:OfficeEquipment2023-03-3114402511core:AfterOneYear2023-03-3114402511core:WithinOneYear2023-03-3114402511core:ListedExchangeTraded2023-03-3114402511core:UnlistedNon-exchangeTraded2023-03-3114402511core:ShareCapital2023-03-3114402511core:SharePremium2023-03-3114402511core:RevaluationReserve2023-03-3114402511core:OtherReservesSubtotal2023-03-3114402511core:RetainedEarningsAccumulatedLosses2023-03-3114402511core:NetGoodwill2022-10-0614402511core:IntangibleAssetsOtherThanGoodwill2022-10-0614402511core:LandBuildings2022-10-0614402511core:PlantMachinery2022-10-0614402511core:Vehicles2022-10-0614402511core:FurnitureFittings2022-10-0614402511core:OfficeEquipment2022-10-0614402511core:AfterOneYear2022-10-0614402511core:WithinOneYear2022-10-0614402511core:ListedExchangeTraded2022-10-0614402511core:UnlistedNon-exchangeTraded2022-10-0614402511core:ShareCapital2022-10-0614402511core:SharePremium2022-10-0614402511core:RevaluationReserve2022-10-0614402511core:OtherReservesSubtotal2022-10-0614402511core:RetainedEarningsAccumulatedLosses2022-10-0614402511core:AfterOneYear2023-04-012024-03-3114402511core:WithinOneYear2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:CostValuation2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3114402511core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3114402511core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3114402511core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3114402511core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3114402511bus:Director12023-04-012024-03-31

CHRISTA GDP PHARMA LTD

Registered Number
14402511
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2024

CHRISTA GDP PHARMA LTD
Company Information
for the year from 1 April 2023 to 31 March 2024

Director

MARTIN, Christopher Thomas

Registered Address

35 St. Leonards Road
Northampton
NN4 8DL

Registered Number

14402511 (England and Wales)
CHRISTA GDP PHARMA LTD
Balance Sheet as at
31 March 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets31,478805
1,478805
Current assets
Debtors1182,390
Cash at bank and on hand20,5637,104
20,6819,494
Creditors amounts falling due within one year4(12,758)(4,460)
Net current assets (liabilities)7,9235,034
Total assets less current liabilities9,4015,839
Net assets9,4015,839
Capital and reserves
Called up share capital100100
Profit and loss account9,3015,739
Shareholders' funds9,4015,839
The financial statements were approved and authorised for issue by the Director on 10 April 2024, and are signed on its behalf by:
MARTIN, Christopher Thomas
Director
Registered Company No. 14402511
CHRISTA GDP PHARMA LTD
Notes to the Financial Statements
for the year ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
2.Average number of employees

20242023
Average number of employees during the year00
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 April 23930930
Additions1,0381,038
At 31 March 241,9681,968
Depreciation and impairment
At 01 April 23125125
Charge for year365365
At 31 March 24490490
Net book value
At 31 March 241,4781,478
At 31 March 23805805
4.Creditors: amounts due within one year

2024

2023

££
Taxation and social security11,8443,848
Other creditors914612
Total12,7584,460
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.